A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Evaluation of the Safety and Efficacy of Once-Daily Administrations of TZP-102 for the Treatment of Symptomatic Gastroparesis in Patients with Diabetes Mellitus

Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Evaluation of the Safety and Efficacy of Once-Daily Administrations of TZP-102 for the Treatment of Symptomatic Gastroparesis in Patients with Diabetes Mellitus

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Jun 2013

At a glance

  • Drugs TZP 102 (Primary)
  • Indications Diabetic gastroparesis
  • Focus Therapeutic Use
  • Sponsors Tranzyme Pharma
  • Most Recent Events

    • 05 Oct 2012 Results presented at the 48th Annual Meeting of the European Association for the Study of Diabetes.
    • 10 May 2011 Results presented at Digestive Disease Week 2011.
    • 10 May 2011 Results presented at the Digestive Disease Week (DDW-2011).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top